DOCSLIB.ORG

M&G Investment Funds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
M&G Investment Funds M&G Investment Funds (3) Annual Long Report and audited Financial Statements for the year ended 30 June 2021 Contents Authorised Corporate Director’s Report.......... 1 Directors’ statement ......................... 4 Depositary’s Responsibilities and Report......... 5 Independent Auditor’s Report .................. 6 Financial statements and notes................. 9 Authorised Corporate Director’s Reports, including the financial highlights and financial statements and notes for: M&G Corporate Bond Fund ................... 15 M&G Dividend Fund ......................... 57 M&G Emerging Markets Bond Fund ............ 90 M&G European Corporate Bond Fund .......... 130 M&G Global Government Bond Fund ........... 167 M&G Recovery Fund ......................... 202 M&G Smaller Companies Fund ................ 238 Other regulatory disclosures ................... 266 Glossary .................................... 267 Annual Long Report and audited Financial Statements • June 2021 Authorised Corporate Director’s Report The Authorised Corporate Director (ACD) of M&G A shareholder is not liable for the debts of the Company Investment Funds (3) presents its Annual Long Report and will never be liable to make any further payment to and audited Financial Statements for the year ended the Company after paying the purchase price of the 30 June 2021. shares. The audited financial statements of Fund managers M&G Investment Funds (3) and the investment report The following fund managers are employed by M&G FA and audited financial statements and notes of each Limited which is an associate of M&G Securities sub-fund are presented in their individual sections of Limited. this report as set out in the contents page. M&G Corporate Bond Fund Please note that we have included an explanation of key Richard Woolnough & Ben Lord investment terminology in the ‘Glossary’ (at the back of this report). M&G Dividend Fund Michael Stiasny Company information M&G Emerging Markets Bond Fund Claudia Calich M&G Investment Funds (3) is an umbrella Open-Ended Investment Company (OEIC) and contains seven M&G European Corporate Bond Fund sub-funds, hereinafter referred to as ‘funds’ in the rest Stefan Isaacs of this report. Each fund is a UCITS (Undertakings for M&G Global Government Bond Fund Collective Investment in Transferable Securities) Eva Sun-Wai scheme as defined in the Collective Investment Please note that effective from 4 January 2021, Eva Sun-Wai replaced Schemes sourcebook, as issued (and amended) by the Claudia Calich as fund manager. Financial Conduct Authority (FCA). This OEIC is an M&G Recovery Fund Investment Company with Variable Capital (ICVC) Michael Stiasny incorporated under the Open-Ended Investment Please note that effective from 31 December 2020, Michael Stiasny Companies Regulations 2001. It is authorised and replaced Tom Dobell as fund manager. regulated by the FCA under the Financial Services and M&G Smaller Companies Fund Markets Act 2000. Garfield Kiff The Company was authorised on 8 August 2001 and Please note that effective from 1 July 2021, James Taylor replaced Garfield was launched on 7 March 2002, following the Kiff as fund manager. conversion of a series of authorised unit trusts. ACD The Company’s principal activity is to carry on business M&G Securities Limited, as an OEIC. The Company is structured as an umbrella 10 Fenchurch Avenue, London EC3M 5AG, UK company, and different funds may be established by Telephone: 0800 390 390 (UK only) the ACD from time to time with the agreement of the (Authorised and regulated by the Financial Conduct Depositary and approval from the FCA. The funds are Authority. M&G Securities Limited is a member of the operated separately and the assets of each fund are Investment Association and of the Investing and Saving managed in accordance with the investment objective Alliance) and policy applicable to that fund. As at 30 June 2021 none of the funds held shares of the Directors of the ACD N J Brooks*, C Dobson (non executive director), other funds within this OEIC. S A Fitzgerald, P R Jelfs, M McGrade (non executive director), L J Mumford * Appointed 19 May 2021. Annual Long Report and audited Financial Statements • June 2021 1 Authorised Corporate Director’s Report Investment manager On 15 December 2020, the following share classes M&G Investment Management Limited, were closed within the M&G Global Government Bond 10 Fenchurch Avenue, London EC3M 5AG, UK Fund: Euro Class ‘A’ Income, Euro Class ‘A’ Telephone: +44 (0)20 7626 4588 Accumulation, Euro Class ‘C’ Accumulation, Swiss franc (Authorised and regulated by the Financial Conduct Class ‘A’ Accumulation, Swiss franc Class ‘C’ Authority) Accumulation, US dollar Class ‘A’ Income, US dollar Class ‘A’ Accumulation and US dollar Class ‘C’ Registrar Accumulation. SS&C Financial Services Europe Ltd, There was a reduction in the annual charge on some SS&C House, St. Nicholas Lane, Basildon, Essex share classes from 15 February 2021. The reduction in SS15 5FS, UK annual charge varies across the M&G funds and the (Authorised and regulated by the Financial Conduct detail was communicated in the shareholder letter Authority) dated 15 January 2021. Depositary On 15 March 2021 the Sterling Class ‘PP-H’ Income NatWest Trustee & Depositary Services Limited, share and Sterling Class ‘PP-H’ Accumulation share House A, Floor 0, 175 Glasgow Road, Gogarburn, were launched in M&G Emerging Markets Bond Fund. EdinburghEH121HQ,UK On 25 March 2021 the investment policy was changed (Authorised and regulated by the Financial Conduct for M&G Corporate Bond Fund. Authority) On 19 April 2021 the investment objective and Independent auditor benchmark were changed for M&G Global Government Ernst & Young LLP Bond Fund. Atria One, 144 Morrison Street, Edinburgh EH3 8EX, UK The World Health Organisation declared the COVID-19 outbreak a pandemic on 11 March 2020. Annual value assessment The COVID-19 pandemic has been an unprecedented An annual assessment report is available which shows event. After an initial period of increased market the value provided to investors in each of volatility and uncertainty, there has been a marked M&G’s UK-based funds. The assessment report recovery in global markets, bolstered by supportive evaluates whether M&G’s charges are justified in the economic policies from governments and positive news context of the overall service delivered to its investors. on vaccines for COVID-19. The report can be found at www.mandg.co.uk/valueassessment The ACD continues to monitor the ongoing operational risks that are posed to the Company and its service providers due to global and local movement restrictions Important information that have been enacted by various governments. On 16 July 2020, the following share classes were closed within the M&G Global Government Bond Investor information Fund: Euro Class ‘C’ Income and US dollar Class ‘C’ Income. The Prospectus, Instrument of Incorporation, Key Investor Information Documents, costs and charges On 15 December 2020, the following share classes illustration, the latest Annual or Interim Investment were closed within the M&G Corporate Bond Fund and Report and Financial Statements as well as a list of the M&G Recovery Fund: Euro Class ‘A’ Accumulation purchases and sales are available free of charge on and Euro Class ‘C’ Accumulation. request from the following addresses. The Instrument 2 Annual Long Report and audited Financial Statements • June 2021 Authorised Corporate Director’s Report of Incorporation can also be inspected at our offices or attheofficeoftheDepositary. Customer services and administration for UK clients: M&G Securities Limited, PO Box 9039, Chelmsford CM99 2XG, UK Please remember to quote your name and M&G client reference and sign any written communication to M&G. Failure to provide this will affect your ability to transact with us. Telephone: 0800 390 390 (UK only) For security purposes and to improve the quality of our service, we may record and monitor telephone calls. You will require your M&G client reference. Failure to provide this will affect your ability to transact with us. Customer services and administration for non-UK clients: M&G Securities Limited, c/o RBC I&TS, 14, Porte de France, L-4360 Esch-sur-Alzette, Grand Duchy of Luxembourg Please remember to quote your name and M&G client reference and sign any written communication to M&G. Failure to provide this will affect your ability to transact with us. Telephone: +352 2605 9944 Email: [email protected] For security purposes and to improve the quality of our service, we may record and monitor telephone calls. You will require your M&G client reference. Failure to provide this will affect your ability to transact with us. Swiss paying agent and representative: Société Générale, Paris, Zurich Branch, Talacker 50, 8021 Zurich, Switzerland Annual Long Report and audited Financial Statements • June 2021 3 Authorised Corporate Director’s Report Authorised Corporate Director’s Responsibilities The Authorised Corporate Director (ACD) is required to prepare annual and interim long reports for the Company. The ACD must ensure that the financial statements, contained in this report, for each of the funds are prepared in accordance with the Investment Association Statement of Recommended Practice for Financial Statements of UK Authorised Funds (SORP) and UK Financial Reporting Standards, and give a true and fair view of the net revenue or expenses and net capital gains or losses for the accounting period, and the financial position at the end of that period. The ACD is required to keep proper accounting records, and to manage the Company in accordance with the Collective Investment Schemes sourcebook, as issued (and amended) by the FCA, the Instrument of Incorporation and the Prospectus, and to take reasonable steps for the prevention and detection of fraud or other irregularities. Additionally, the ACD is responsible for preparing the financial statements on a going concern basis unless it is appropriate to presume that the Company or its sub-funds will not continue in operation.
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • This Announcement Contains Inside Information for the Purposes Of
    RNS Number : 8738R Esken Limited 11 March 2021 This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. 11 March 2021 Esken Limited ("Esken" or "the Group") Trading update Esken, the aviation and energy infrastructure group, issues the following update on trading for the year to 28 February 2021. Summary • Strict financial discipline has resulted in £77.4m of cash and undrawn bank facilities available as at 28 February. • London Southend Airport benefited from continued activity through its global logistics operation. • Gate fees at Stobart Energy have continued to improve toward pre-COVID-19 levels. • Esken is progressing a range of options regarding Stobart Air & Propius and expects to bring the matter to conclusion in the near term. David Shearer, Executive Chairman said, "We have continued to deliver against the strategy we set out at the time of our capital raise in June 2020 despite the business interruption caused by COVID-19 extending far beyond all reasonable expectations at that time." "Esken is becoming a more focused business. We divested the Rail & Civils division and remain committed to exiting Stobart Air and Propius. As a Board, we are undertaking a review of our strategic options in light of the impact of the pandemic. We are doing this to ensure that we protect the capability of our core operations and focus on delivering value for shareholders." "We continue to maintain strict financial discipline. This has allowed us to minimise cash burn and protect our liquidity position.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • Witan Investment Trust Plc Portfolio Listing As at 31.07.2021
    WITAN INVESTMENT TRUST PLC PORTFOLIO LISTING AS AT 31.07.2021 SECURITY % OF TOTAL INVESTMENT APAX GBL ALPHA NPV 2.98 ALPHABET A USD0.001 1.88 PRINCESS PRIVATE EQTY HLDGS ORD EUR0.001 1.87 ELECTRA PRIVATE GBP 0.25 1.53 SYNCONA ORD NPV 1.34 CHARTER COMMUNICATIONS -A USD0.001 1.32 BLACKROCK WORLD MINING TST ORD GBP0.05 1.31 ARCELORMITTAL NPV 1.30 DIAGEO GBP28.93518 1.27 PAYPAL HLDGS USD0.0001 1.16 INTUIT USD0.01 1.11 HEINEKEN HLDGS EUR1.6 1.08 SCHRODER REAL ESTATE INV TST ORD NPV 1.03 THERMO FISHER SCIENTIFIC USD1 1.02 UNILEVER GBP0.031111 1.00 BT GRP ORD GBP0.05 0.98 NATWEST GRP GBP1 0.91 TAIWAN SEMICONDUCTOR MANUFACTURING 1 ADS REP 5 ORD TWD10 0.89 FACEBOOK A USD0.000006 0.89 FREEPORT-MCMORAN USD0.1 0.89 RELX GBP0.144397 0.86 NATL GRID ORD GBP0.12431289 0.85 LLOYDS BANKING GRP GBP0.1 0.85 VIVENDI EUR5.5 0.82 WALT DISNEY CO USD0.01 0.82 LINDENWOOD USD 0.81 BAE SYSTEMS ORD GBP0.025 0.80 MICROSOFT CORP USD0.00000625 0.79 SHOPIFY A NPV 0.79 CANADIAN PACIFIC RAILWAY NPV 0.77 VINCI EUR2.5 0.77 LONDON STK EXCHANGE GRP GBP0.06918605 0.76 SMURFIT KAPPA GRP EUR0.001 0.76 UNITEDHEALTH GRP USD0.01 0.75 PEPSICO USD0.017 0.74 MONDELEZ INTL USD0.01 0.74 PEARSON GBP0.25 0.70 NINTENDO CO NPV 0.69 LVMH MOET HENNESSY LOUIS VUI EUR0.3 0.68 VH GBL SUSTAINABLE ENERGY NPV 0.67 MOODYS CORP USD0.01 0.67 CRH EUR0.32 0.66 FISERV USD0.01 0.66 LAM RESEARCH CORP COM USD0.001 0.65 BREEDON GRP NPV 0.64 FLUTTER ENT GBP0.09 0.63 SHISEIDO CO NPV 0.63 COOPER COS COM USD0.10 0.63 MASTERCARD A USD0.0001 0.62 MERCADOLIBRE COM USD0.001 0.61 BECTON DICKINSON & CO USD1 0.59 SAFRAN EUR0.20 0.58 ILLUMINA COM USD0.01 0.58 PRYSMIAN EUR NPV 0.57 BAXTER INTL COM USD1 0.56 DELTA AIR LINES USD0.0001 0.55 APPLIED MATERIALS USD0.01 0.55 STRYKER CORP USD0.1 0.54 HARGREAVES LANSDOWN GBP0.004 0.54 SONIC HEALTHCARE NPV 0.53 ADYEN NPV 0.53 CATALENT USD0.01 0.52 WEST PHARMACEUTICAL SERV USD0.25 0.51 INTERCONTINENTAL EXCHANGE GRP USD0.01 0.50 KAO CORP NPV 0.50 TAIWAN SEMICONDUCTOR MANUFACTURING TWD10 0.48 EBAY USD0.001 0.48 REMY COINTREAU EUR1.6 0.48 Please see the disclaimer at the end of this document.
    [Show full text]
  • THE MONTHLY January 2019
    THE MONTHLY January 2019 FJanuary 2019 Table of contents About our January feature article ...................................................................................... 3 Hardman & Co Healthcare Index ....................................................................................... 3 Review of 2018 ...................................................................................................................... 4 Movers and shakers ............................................................................................................... 6 About the authors .............................................................................................................. 10 Company research ............................................................................................................. 11 1pm plc ................................................................................................................................... 12 Advanced Oncotherapy ..................................................................................................... 13 Allergy Therapeutics ........................................................................................................... 14 Alliance Pharma .................................................................................................................... 15 Arbuthnot Banking Group ................................................................................................. 16 Avatca ....................................................................................................................................
    [Show full text]
  • Gene Therapy Is
    Gene therapy is now Annual report and accounts 2017 Oxford BioMedica in brief Oxford BioMedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector and cell therapy research, development and bioprocessing. Gene and cell therapy is the treatment of disease by the delivery of therapeutic DNA into a patient’s cells. This can be achieved either in vivo (referred to as gene therapy) or ex vivo (referred to as cell therapy), the latter being where the patient's cells are genetically modified outside the body before being re-infused. Oxford BioMedica is focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Introducing Oxford BioMedica 1 At the front and centre 3 Multi-billion $ market sector 3 Targeting unmet needs 4 Enabling new treatments 4 Sharing
    [Show full text]
  • Representing the Child's Memory: an Ulster
    Patrick Doherty PhD Creative Writing February 2020 REPRESENTING THE CHILD’S MEMORY: AN ULSTER CHILDHOOD RECONSTRUCTED by PATRICK DOHERTY A thesis submitted in partial fulfilment for the requirements for the degree of Doctor of Philosophy at the University of Central Lancashire FEBRUARY 2020 1 Patrick Doherty PhD Creative Writing February 2020 2 Patrick Doherty PhD Creative Writing February 2020 ABSTRACT In this thesis I examine the potential for the self-representation of an Ulster, rural, Catholic childhood in 1950s -70s through the creative practice of writing my own memoir in the first person, present tense and the aging child’s point of view, in a fractured, non- linear narrative. My memoir uses the child’s language appropriately in accordance with my understanding of child development gained from a lifetime of teaching. My memoir underscores, through personal experience, the revelations of child abuse over the past thirty years as exposed in the Ryan Report in 2009. My narrative strategy of using the first person and child’s point of view demonstrate the impact upon the individual child of a society’s suppression of the silence and violence within the home, school and church. My memoir is accompanied by an exegesis which critically examines my creative writing output and practice. My memoir contributes to the development of a young child’s cognition and its development through to adulthood. It is a contribution to an evolving body of memoir in response to social and familial conditions in mid-twentieth century Ireland. 3 Patrick Doherty PhD Creative Writing February 2020 TABLE OF CONTENTS Abstract P.
    [Show full text]
  • Richard Johnson
    Richard Johnson Partner Corporate and M&A Rising Stars: Europe's Best Up and Coming Private Equity Lawyers 2020 Primary practice Corporate and M&A 29/09/2021 Richard Johnson | Freshfields Bruckhaus Deringer About Richard Johnson <div> <p><strong>Richard advises the world&rsquo;s leading financial sponsors and multinational corporations, often in the infrastructure space.&nbsp; </strong></p> <p>He has experience across the corporate spectrum, with a particular focus on cross-border private and public M&amp;A.&nbsp;</p> <p>Richard has worked in our London, Hong Kong and Beijing offices, and spent time at Heathrow on secondment to airports operator BAA.</p> </div> Recent work <p><strong>Richard has recently advised:</strong></p> <ul> <li><strong>ArcLight Capital Partners</strong>, including on the disposals of North Sea Midstream Partners and Bizkaia Energia.</li> <li><strong>Berry</strong> <strong>Global</strong>, including on its recommended takeover of London- listed RPC Group plc.</li> <li><strong>BP plc</strong>, including&nbsp;on its acquisition of BHP Billiton&rsquo;s onshore US shale assets.</li> <li><strong>Debenhams </strong>(formerly listed in London), including on its financial restructuring and sale of IP to boohoo.</li> <li><strong>DP World </strong>(listed in Dubai) in relation to the recommended offer from its controlling shareholder Port &amp; Free Zone World FZE.</li> <li><strong>Esken </strong>(listed in London), including in relation to transactions involving London Southend Airport, Stobart Air and Carlisle Lake District
    [Show full text]